// Company Overview //
| Stock Name | 思派健康 |
|---|---|
| Stock Code | 00314 |
| Company Full Name | 思派健康 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事特藥藥房業務、醫生研究協助業務及健康保險服務業務。 |
| Listing Date | 2022-12-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省廣州市廣州國際生物島螺旋大道51號官洲生命科學創新中心A塔26樓11–13室 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.medbankshealthtech.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2022-12-12 |
| Offer Price | HK$ 18.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | — shares |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | — |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 18,451,200 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | -3.10 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 65,300,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 23.7 |
| First Day Change | 34.41% |
| First Day Volume | 2174600.0 |
| First Day Turnover | 52611300.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約87%或約104.8百萬港元預計將用于業務擴張； 2、約13%或約15.6百萬港元預期將用于技術研發及提升技術基礎設施。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
摩根士丹利亚洲有限公司
海通国际资本有限公司
整体协调人 (2)
摩根士丹利亚洲有限公司
海通国际证券有限公司
联席账簿管理人 (2)
摩根士丹利亚洲有限公司
海通国际证券有限公司
联席牵头经办人 (5)
摩根士丹利亚洲有限公司
海通国际证券有限公司
富途证券国际（香港）有限公司
迈时资本有限公司
一盈证券有限公司
// Cornerstone Investors //
This stock has no cornerstone investors.
// Directors & Management //
| Chairman | 馬旭廣 |
|---|---|
| Company Secretary | 任娜 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 騰訊控股有限公司(27.41%);FMR LLC(9.09%);馬旭廣(7.47%);Ching Hsin Chang Jimmy(6.96%),方舟信托(香港)有限公司(5.30%);李繼(5.24%) |
|---|
